KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Nektar Therapeutics (NKTR) Other Gross PP&E Adjustments (2016 - 2025)

Nektar Therapeutics has reported Other Gross PP&E Adjustments over the past 16 years, most recently at -$21.2 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$21.2 million for Q4 2025, up 24.96% from a year ago — trailing twelve months through Dec 2025 was -$21.2 million (up 24.96% YoY), and the annual figure for FY2025 was -$21.2 million, up 24.96%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$21.2 million at Nektar Therapeutics, down from -$7.2 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for NKTR hit a ceiling of $43.8 million in Q4 2021 and a floor of -$125.0 million in Q1 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$28.9 million (2023), compared with a mean of -$41.6 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 126.75% in 2021 and later crashed 278.29% in 2022.
  • Nektar Therapeutics' Other Gross PP&E Adjustments stood at $43.8 million in 2021, then crashed by 278.29% to -$78.1 million in 2022, then surged by 51.08% to -$38.2 million in 2023, then increased by 25.96% to -$28.3 million in 2024, then increased by 24.96% to -$21.2 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$21.2 million (Q4 2025), -$7.2 million (Q3 2025), and -$7.6 million (Q2 2025) per Business Quant data.